Has Marian Georgiev, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,996 in general payments to Marian Georgiev, MD across 73 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marian Georgiev, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marian Georgiev, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marian Georgiev, MD

Geriatric Psychiatry · Reading, PANPI 1407099096

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.9% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Alkermes, Inc. at 24.6% of the total.

$1,996in general payments, 2019–2025

Across 73 payments — averaging $27.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alkermes, Inc.$491
Otsuka America Pharmaceutical, Inc.$479
Teva Pharmaceuticals USA, Inc.$282
Indivior Inc.$180
Johnson & Johnson$154
Neurocrine Biosciences, Inc.$150
plus $262 from 5 others

What the payments were for

Food & beverage$1,87394%
Education$1236%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alkermes, Inc.	14	$491
Otsuka America Pharmaceutical, Inc.	18	$479
Teva Pharmaceuticals USA, Inc.	10	$282
Indivior Inc.	8	$180
Johnson & Johnson	6	$154
Neurocrine Biosciences, Inc.	7	$150
Merck	1	$75
E.r. Squibb & Sons, L.L.C.	3	$72
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	4	$64
Braeburn Inc.	1	$26
Sunovion Pharmaceuticals Inc.	1	$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,996 in reported general payments places this provider in the 80th percentile of 31 geriatric psychiatry providers in Pennsylvania.

See all geriatric psychiatry providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$45,736

Medicare patients

Services billed

829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Abilify MaintenaAripiprazole	39	$112,715
CaplytaLumateperone Tosylate	16	$28,258
Fluphenazine Decanoate	25	$1,906
Clozapine	32	$1,860
Oxcarbazepine	20	$750
Trazodone Hcl	42	$462
Lorazepam	44	$360
Divalproex Sodium	12	$351
Aripiprazole	21	$334
Divalproex Sodium ErDivalproex Sodium	11	$254
Quetiapine Fumarate	23	$196
Mirtazapine	16	$169
Lamotrigine	25	$141
Hydroxyzine Pamoate	11	$115
Topiramate	17	$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena	$479	$112,71539 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta	$64	$28,25816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 31 geriatric psychiatry providers in Pennsylvania.